Monday, August 17, 2020

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Top Health News -- ScienceDaily https://ift.tt/317NlC5
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists reverse liver cell aging and cut Alzheimer’s-linked protein in half

A surprising discovery suggests that rejuvenating the liver could help protect against Alzheimer’s disease and heart disease. USC researcher...